Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatiquinone in inherited mitochondrial disease
NCT05218655Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of vatiquinone in mitochondrial disease, sponsored by PTC Therapeutics, Inc.. Started Jun 2022; status: completed.
02
Drugs
vatiquinone
03
Conditions
mitochondrial disease
Beyond the preview
Go deeper on NCT05218655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218655.